Introduction
The folate pathway, commonly known as folate-mediated one-carbon metabolism, refers to a system consisting of a number of interdependent pathways that use a family of structurally similar and metabolically inter-convertable enzyme cofactors. These cofactors are structurally based on tetrahydrofolate (THF) and are used to chemically activate single carbons (one-carbon units) ( Figure 1 ). They are key components in the synthesis of purine and thymidine nucleotides and in the methylation of homocysteine to methionine, a process that is crucial to the regulation of normal patterns of DNA methylation ( Figure 1 ). The one-carbon folate metabolism and methionine synthesis pathways involve a considerable number of enzymes and carrier proteins ( Figure 1 ).
Many genetic studies have been undertaken looking for associations between disease and polymorphisms in the multiple genes involved in one-carbon metabolism and methionine synthesis pathways. [1] [2] [3] [4] These studies have focused, primarily, on identifying associations between disease risk and non-synonymous (ns) and previously well-characterized polymorphisms. However, given the number of genes that are involved in the folate pathway (Figure 1 ), investigation of disease associations with other, less-well investigated genomic loci may be warranted and may uncover new genetic associations.
This review discusses the importance of the one-carbon metabolism pathway in physiology and disease, and how genetic variation predisposes to disease and variability in response to medications. We have undertaken both a literature review and a bioinformatic analysis of the pathway, and will discuss the limitations of current approaches and of in silico tools that are used to predict the functionality of ns single nucleotide polymorphisms (nsSNPs).
Literature searching methods
Journal articles relating to disease associations with 5,10-methylenetetrahydrofolate reductase (MTHFR), dihydrofolate reductase (DHFR) and thymidylate synthase (TYMS) polymorphisms were identified in National Center for Biotechnology Information (NCBI) PubMed database (http:// www.ncbi.nlm.nih.gov/sites/entrez?db ¼ pubmed), using the search terms 'genetics' and 'MTHFR,' 'DHFR' or 'TYMS,' respectively. In the case of MTHFR, articles were limited to 'Meta-analysis' because of the very large number of individual studies. In all cases, articles were limited to English language only.
Folate pathophysiology and disease
Elevation of homocysteine is a sensitive marker of folate deficiency. Homocysteine, a sulfur-containing amino acid, cannot be obtained through any dietary source. It is solely the product of the methylation cycle, which is responsible for its removal as well as its formation ( Figure 1 ). Elevated homocysteine levels and folate deficiency have been associated with a number of disorders, including cardiovascular disease, psychiatric disorders, adverse pregnancy outcomes, cancer and osteoporosis. Many of these disorders can be explained, in part, by the interruption of folatedependant one-carbon transfer and by the subsequent effect on methionine, purine and thymidylate synthesis ( Figure 1 ). Three specific but inter-linked underlying causes are believed to be important: common polymorphisms within genes of the one-carbon folate pathway; impaired gene expression of folate-metabolizing genes; and poor dietary folate intake. The number of diseases associated with altered one-carbon metabolism has led to extensive investigations of the genetic variants in this pathway, their metabolic effects and the associated risk of chronic diseases. 5, 6 Folate pharmacology
Folate supplementation
Folate is found in abundance in a number of dietary sources, particularly leafy vegetables, dried beans and peas. Some foods (particularly breakfast cereals) are also fortified with folate in the form of the synthetic analog, folic acid, which can also be taken as a dietary supplement. Folic acid supplementation has been used as a preventive strategy in a number of clinical conditions. In 1998, a recommended dietary allowance of 400 mg day À1 of folic acid intake was established in the United States.
Neural tubule defects
Given its key role in thymidine synthesis and thus in DNA replication, folate is particularly important during periods of rapid cell division such as pregnancy. Adequate folate intake during the peri-conceptional periods protects against congenital malformations such as neural tubule defects (NTDs). 7 The risk of NTDs is significantly decreased when a healthy diet is supplemented with multivitamins, principally folic acid. 8, 9 Indeed, studies in the United States have suggested a significant decrease in the prevalence of spina bifida and anencephaly as the Food and Drug Administration (FDA) mandated the addition of folic acid to all enriched cereal grain products by January 1998.
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Cancer Low-plasma folate levels have been associated with an increased incidence of a number of types of cancer. Folate deficiency seems to predispose normal tissue to neoplastic transformation, and folate supplementation can suppress the development of tumors in normal tissue. 13 For instance, a 20-40% reduction in the risk of colorectal cancers and precursory adenomas has been reported in individuals with the highest folate status as against those with the lowest. 13 A number of meta-analyses have postulated an association between high folate and a mild protective effect against the risk of several cancers, including colorectal, 14 pancreatic, esophageal, gastric, 15 oral 16 and ovarian. 17 Conversely, and controversially, there is some evidence to suggest that high folate may indeed be a risk factor for some forms of cancer. A double-blind, placebo-controlled, randomized trial showed that the folic acid supplementation was associated with higher risk of colorectal adenoma and prostate cancer. 18 There is also evidence to suggest that folic acid supplementation increases the risk of breast cancer in postmenopausal women. 19 Whether these are true associations or epiphenomena requires further study, but nevertheless highlights the complexity of the one-carbon folate pathway and its interaction with carcinogenesis.
Psychiatric disorders
Folate supplementation may be beneficial in the treatment of depressive illness as an adjuvant to antidepressant therapy. 20 However, the small numbers of studies undertaken so far limit the conclusions that can be drawn, although further studies are underway. These include a multicentered double-blind, placebo-controlled, randomized trial of folic acid augmentation of pragmatic antidepressant treatment of moderate-to-severe depression (FolATED). 21 A possible association between folate deficiency and schizophrenia has also been reported. 22 However, further investigation is required to determine whether folate supplementation would be of benefit in treating schizophrenic patients. There is also evidence that folic acid may improve cognitive function. In a 3-year study of the elderly, a daily intake of 800 mg of oral folic acid significantly improved those domains of cognitive function that deteriorate with age. 23 
Cardiovascular disease
There has been a great deal of focus on the association between serum homocysteine levels and the risk of cardiovascular disease (CVD). According to a meta-analysis, a decrease in serum homocysteine by 3 mmol l À1 should reduce the risk of ischemic heart disease deep vein thrombosis and stroke by 16, 25 and 24%, respectively. 24 Such a reduction in homocysteine would be achievable by folic acid supplementation of 0.8 mg day À1 . 25 Other studies, however, have suggested that folic acid intervention, in the presence and absence of vitamin B 6 , does not lower the risk of recurrent cardiovascular disease or death after acute myocardial infarction. 26 This finding is mirrored in studies in which patients with vascular disease showed no decrease in the risk of major cardiovascular events after supplementation with folic acid and vitamin B 6 and B 12 . 27 Despite the many apparently beneficial effects of folate supplementation, and its low incidence of toxicity, 28 some concern has been expressed regarding the interaction between vitamin B 12 and folic acid, primarily in the elderly population. Folic acid is able to mask nervous system changes caused by vitamin B 12 deficiency by correcting the associated anemia. The upper limit of recommended dietary intake of 1 mg, set by the Institute of Medicine, was believed to be unlikely to produce masking. 29 However, this has proved controversial with some, suggesting that intake of o1 mg may exert a masking effect. 30 Indeed, the United Kingdom's Food Standards Agency (FSA) Board recommended against mandatory folic acid fortification, partly due to the potential masking of vitamin B 12 deficiency until May 2007, when mandatory fortification was finally agreed (http://www.food.gov.uk/healthiereating/folicfortification/).
Molecular and population genetics of the one-carbon folate pathway
The sheer number of recorded variants within the genes of the one-carbon and methionine metabolism pathways highlights just how many avenues of investigation are left unexplored in the search for genetic risk factors for disease and inter-individual variability in response to drugs. Most attention has focused on a small number of well-characterized polymorphisms in functionally well-defined genes. It is our intention to describe these, and additionally discuss those variants that have been less well-characterized. Table 2 ). The most commonly studied polymorphism in the TYMS gene is a 28-bp tandem repeat region in the 5 0 -untranslated region (UTR). First described in 1995, 33, 34 it was observed in vitro that an increase in the number of repeats resulted in a stepwise increase in the TYMS mRNA expression. In vivo studies in human gastrointestinal tumor samples were consistent with the in vitro findings: TSER*3 carriers showed significant increases in both mRNA and protein expression compared with TSER*2 individuals. 35 A novel G4C polymorphism in the 12th nucleotide of the TSER*3 has also been identified. This allelic variant has been shown to decrease TYMS expression. 36 A third characterized polymorphism in the TYMS gene is a 6-bp deletion in the 3 0 -UTR, 447 bp downstream of the stop codon. 37 Homozygotes for this deletion show lower mRNA expression than homozygotes for the presence of the 6-bp deletion, 38 which is also a determinant of elevated red blood cell folate. 39 DHFR DHFR (EC, 1.5.1.3) reduces dihydrofolate (DHF), formed during dTMP synthesis, back to THF, which subsequently rejoins the pool of folate cofactors. All folate forms in vitamin supplements and fortified food are in the form of folic acid, an unreduced folate, and requires DHFR for reduction. Thus, DHFR is vital to the bioavailability of folic acid in cellular reactions. The importance of the DHFR protein is perhaps illustrated by the finding that the coding region is highly conserved with no allelic variants having been identified. 40 There are three non-coding polymorphisms (in the 5 0 upstream region, intron 1 and 3 0 -UTR) that have been the subject of a number of association studies (Table 3 ). The 19-bp deletion polymorphism in intron 1 in the DHFR gene has been associated with a number of diseases 41 (Table 3) . Individuals homozygous for the deletion (À/À) have lower mean plasma total homocysteine than those homozygous for the insertion ( þ / þ ), 40 with the (À/À) individuals also having been shown to have 4.8-fold greater DHFR mRNA expression in lymphocytes compared with ( þ / þ ) carriers. 42 The 5 0 -upstream 9-bp repeat polymorphism (homozygous 6R carriers) 43 and 3 0 -UTR SNP (rs34764978) (C/T and T/T carriers) 44 have also been associated with enhanced mRNA expression.
MTHFR
One-carbon metabolism genetic variant phenotypes Besides well-characterized polymorphisms in genes such as MTHFR, TYMS and DHFR, a number of genetic variants in other genes in these pathways ( Figure 1 ) have been identified. Hyperhomocysteinemia and hypermethionemia have been reported as clinical consequences of functional polymorphisms in genes involved in the methionine synthesis pathway.
Homocystinuria and hypomethionemia
First described in 1962 in a cohort of patients with mental retardation, 45 homocystinuria is the result of impairment of the methionine synthesis pathway. Major clinical manifestations affect the central nervous, vascular and skeletal systems. Sequence variations in the cystathionine-betasynthase gene (CBS; EC, 4.2.1.22) leading to CBS protein deficiency were the first to be reported as being associated with homocystinuria. 46, 47 More recently, non-synonymous variant alleles have been identified in the CBS and cystathionase (CTH; EC, 4.4.1.1) genes in patients with hyperhomocysteinemia. Homozygotes for the c.1352G4T variant allele (rs1021737) in the CTH gene encoding a p.S403I amino-acid change had significantly higher plasma homocysteine levels than other genotypes in a cohort of 496 Caucasian individuals. 48 An allelic variation in the CBS gene, encoding a p.G307S amino-acid change, has been identified in homocystinuria patients of Celtic ancestry. 49, 50 Another protein variant, p.I278T (rs5742905, c.833T4C), has also been identified in Celtic homocystinuria patients. 50, 51 Heterozygotes for p.I278T, however, are believed to retain some degree of pyridoxine responsiveness to homocystinuria. 50, 51 The elevated homocysteine phenotype in individuals with impaired CBS or CTH is not unexpected, given the key role both have in the synthesis of cystathione from homocysteine ( Figure 1 ).
5-Methyltetrahydrofolate-homocysteine methyltransferase (MTR; EC, 2.1.1.13) is responsible for the final step in the methionine biosynthetic pathway. Mutations in the MTR gene result in methylcobalamin deficiency G (cblG) disorder, which is characterized by homocystinuria, and elevated homocysteine and depleted methionine levels. 52, 53 A common non-synonymous variant (p.P1173L) has been detected in 465% of cblG patients. 54 In addition, 13 novel mutations, including 5 deletions and 2 nonsense mutations were identified, which resulted in the synthesis of truncated proteins that lacked portions critical for enzyme function. Hypermethioninemia Deficiencies in specific genes of the methionine synthesis pathway can result in isolated hypermethioninemia. The most common cause of hypermethioninemia is deficiency of the enzyme methionine adenosyltransferase (MAT 1 alpha) (MAT1A; EC, 2.5.1.6), which catalyzes the transfer of the adenosyl moiety of ATP to methionine to form S-adenosylmethionine, a key component in DNA methylation ( Figure 1 ). Although many patients with MAT deficiency are well clinically, 57 other patients have been reported to have neurological events, 58 including low S-adenosylmethionine, calcification of basal ganglia and demyelination.
Functional genetic polymorphisms in the gene encoding methionine adenosyltransferase 1alpha have been identified in patients with methionine adenosyltransferase deficiency and hypermethionemia. Identified variants of MAT1A include a homozygous truncating mutation identified in an individual with isolated hypermethioninemia 59 and in a girl with MAT deficiency not displaying neurological abnormalities. 60 A heterozygous non-synonymous allelic variant (p.R264H) has also been identified in individuals with autosomal-dominant inheritance of persistent hypermethioninemia. 61 S-adenosylhomocysteine hydrolase (AHCY; EC, 3.3.1.1) is responsible for catalyzing the reversible hydrolysis of S-adenosylhomocysteine to adenosine and homocysteine ( Figure 1) . Deficiency of AHCY protein is another potential cause of hypermethionemia. 62 A case report 62 noted a Croatian boy with hypermethionemia, who possessed two variant alleles encoding non-synonymous changes (p.W112X and p.Y143C) in exon 4 of the AHCY gene. In addition, further coding-region variants in the AHCY gene have been shown to have no significant association with altered plasma homocysteine levels. 63 This was assessed in venous thrombosis patients selected according to their ability to convert methionine to homocysteine (as measured by standardized methionine-loading test).
Clinical implications of other folate metabolism pathway genetic polymorphisms Functional genetic variants in other genes in the methionine synthesis and one-carbon folate metabolism pathways have been implicated in a range of conditions. Given its role in catalyzing the conversion of betaine and homocysteine to One-carbon folate pathway genetics DF Carr et al dimethylglycine and methionine, defects in betaine-homocysteine methyltransferase (BHMT; EC, 2.1.1.5) could lead to homocystinuria. However, to date, no association between elevated homocysteine and functional genetic variants has been observed. An association has been described between a BHMT non-synonymous SNP (encoding a p.R239Q aminoacid substitution) (rs3733890) and the risk of placental abruption 64 and NTDs. 65 Gamma-glutamyl hydrolase (GGH; EC, 3.4.19.9) catalyzes the hydrolysis of folylpoly-gamma-glutamates by removing g-linked glutamate and polyglutamates. Similar to a number of other genes within the one-carbon folate pathway, polymorphisms in the GGH gene have been associated with lower response to administration of the anti-folate, methotrexate, for the treatment of various conditions including rheumatoid arthritis 66 and acute lymphoblastic leukemia. 67 The enzyme 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC; EC, 2.1.2.3) is able to convert 10-formyl THF to THF (Figure 1 ). Earlier studies have described an association between individuals possessing the GG genotype of a common c.347C4G; p.T112S polymorphism (rs2372536) and a decreased response to methotrexate in the treatment of rheumatoid arthritis. 68 A case has also been reported of AICA-ribosiduria, a disease characterized by deficiency in purine biosynthesis, where an infant possessed a K426R amino-acid substitution in ATIC on one allele and a frameshift mutation on the other. 69 This individual presented with dysmorphic features, severe neurological defects and congenital blindness.
Aminomethyltransferase (AMT; EC, 2.1.2.10) forms part of the glycine cleavage system responsible for the catalysis of the conversion of 5,10-methenyl-THF to 5-formyl tetrahydrofolate (Figure 1) . A number of nonsynonymous allelic variants have been identified in patients with typical and atypical nonketotic hyperglycinemia. [70] [71] [72] [73] [74] Typical nonketotic hyperglycinemia presents with seizures, coma and apnea in neonates, whereas the rarer atypical form presents as only developmental delay with some seizures.
Three functional allelic variants (two non-synonymous (p.R135C and p.R299P) in formiminotransferase cyclodeaminase (FTCD; EC, 2.1.2.5/4.3.1.4) have been reported in individuals with glutamate formininotransferase deficiency. 75 This is an autosomal-recessive disorder and the second most common inborn error of folate metabolism. Common features include physical and mental retardation and elevated serum folate.
In addition to genes encoding key enzymes in the onecarbon and methionine synthesis pathways, there is also genetic variability in genes encoding the folate transporter and receptor proteins. Among the most important are solute carrier family 19 (folate influx transporter), member 1 (SLC19A1; MIM# 600424) and folate receptor 1 (FOLR1; MIM# 136430). Coordination of SLC19A1 and FOLR1 is proposed as the mechanism of folate uptake, specifically 5-methyl-THF, in many types of mammalian cells. One-carbon folate pathway genetics
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An amino-acid substitution polymorphism encoding a histidine to arginine change at residue 27 of SLC19A1 (rs1051266) has been associated with decreased methotrexate therapeutic response in individuals with rheumatoid arthritis 68 and childhood acute lymphoblastic leukemia. 76 This same p.H27R polymorphism has also been identified as a risk factor for NTDs. [77] [78] [79] An effect on absorption and cellular translocation, and blood pressure, in the elderly has also been described. 80 FOLR1 polymorphisms have been described earlier as susceptibility factors for gastric cancer in a Chinese population. 81 Cellular folate concentration has been shown to modulate drug-efflux transporters, in particular ABCC1 (MIM# 158343). 82 Consistent with this is the recent finding that genetic variants in ABCC1 act as determinants of response to the anti-folate drug, methotrexate, in patients with psoriasis. 83 
Epigenetics
The one-carbon folate metabolism system is a critical component of global methylation of CpG sites on DNA. Studies in models of folate deficiency both in vitro 84 and in vivo 85 have shown decreased DNA methylation capacity. Associations between global DNA hypomethylation in peripheral leukocytes and homozygosity for the MTHFR C677T polymorphism have also been described. 86, 87 Studies in human vascular smooth muscle cells have suggested that homocysteine could induce demethylation in the promoter region of the MTHFR gene, thus upregulating mRNA expression. 88 It is feasible; therefore, demethylation of the MTHFR promoter may counter the dysfunction of the 677T protein variant in heterozygotes by increasing the expression of the wild-type allele. However, this has not been systematically investigated.
Bioinformatic analysis
As shown in the preceding sections, literature searching methods have shown that the one-carbon and methionine synthesis pathways are complex and consist of a number of enzymes. There is undoubted variability in the function of these enzymes, but to date, most of the studies have focused on several key genetic variants, notably MTHFR c.677C4T. Where there have been studies of the other genes, this has largely focused on rare mutations and often (understandably) in single patients. In order to more fully describe the common and rare variants in these genes in these pathways, and predict their functionality, we also undertook a bioinformatic analysis.
The key genes were identified primarily from the following Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways (http://www.genome.jp/kegg/): One Carbon Pool by Folate (00670), Methionine Metabolism (00680) and Folate Biosynthesis (00790). A list of 26 genes was subsequently compiled (Table 4) .
Validated SNPs within these genes were identified in HapMap Public Release 22, Build 35 (http://www.hapmap. org/cgi-perl/gbrowse/hapmap_B35/). All database SNPs within the CEPH (Utah residents with ancestry from northern and western Europe) population were included and the number of SNPs with a minor allelic frequency (MAF) 45% was determined using the Haploview 3.2 software (http://www.broad.mit.e-du/mpg/haploview/). The number of tagging SNPs within each loci required to represent those with MAF 45% was determined using the 'Tagger' functionality with Haploview by means of a pairwise analysis of linkage disequilibrium with an R 2 threshold of 0.8. Mining of data from HapMap public release #22 (Table 4) showed a total of 1252 validated SNPs within the genomic regions of the 25 included genes, of these, 814 SNPs have a minor allelic frequency of X5%. The analysis of 267 representative tagging SNPs is required to cover the 814 variants based on a pairwise analysis of linkage disequilibrium with an R 2 threshold of 0.8. Further investigation of the NCBI dbSNP Build 129 identified 6742 SNPs within the 25 genes. A total of 127 were classified as non-synonymous SNPs, with 38 of these validated and at a minor allelic frequency of X5%.
In silico prediction of nsSNP functionality. In total, 38 nonsynonymous SNPs were analyzed in silico using a panel of six programs (Table 5 ) to predict the presence of a deleterious effect of the amino-acid substitution (Table 6 ). Each program uses a different approach and can differ in their prediction of deleterious SNPs. For this reason, we decided to analyze SNPs using a panel rather than a specific program. The programs selected can predict deleterious SNPs altering stability, such as a loss of a salt bridge or burial of a polarcharged group and, in some cases, the loss of a key residue involved in an active site of ligand binding. The input data required consisted of structural or sequence information, or in some cases both. Specific information regarding the programs is summarized in Table 5 . By using a range of software platforms, each requiring different input data and using different algorithms, a consensus of opinion on the functionality of nsSNPs within the one-carbon folate pathway was obtained. Essentially, each program used was weighted equally for its prediction of deleterious effects. SNPs were ranked by a score out of 8 (the number of different prediction models used).
The 38 non-synonymous SNPs in the one-carbon folate pathway according to the consensus output of the panel of predictive programs ranked the p.P450R amino-acid substitution of MTRR (rs16879334) as the most likely to exhibit an effect on protein functionality. To the best of our knowledge, however, there are no reports that this polymorphism has shown functional effect on the protein or has been associated with any clinical manifestations. Intriguingly, three polymorphisms commonly associated with clinical manifestations, MTHFR (p.V222A/c.677C4T and p.E429A/c.1298A4G) ( Table 1) , and CTH (p.I403S/ c.1352G4t), 89 were ranked as low as 27, 23 and 36 out of 38, respectively.
The fact that three well-characterized functional polymorphisms were ranked so low within the panel of SNPs raises important issues regarding the use of in silico SNP functionality prediction techniques. These results would One-carbon folate pathway genetics DF Carr et al appear to question the sensitivity of the methodology in identifying functional nsSNPs associated with a characterized phenotype. The limited number of available input protein structures for one-carbon folate pathway genes appears to bias the ranking toward nsSNPs within structurally well-characterized genes. The reason for the absence of structural data is often because of the difficulty in the crystallization process of, for example, membrane-bound proteins. One possible refinement of our protocol might be to produce structural data using homology modeling or threading. However, this can also be prone to considerable error.
Were it possible to produce predictive structural data, these files could only be used by two programs, I-Mutant2.0 and SDM. However, whether the use of in silico predicted structural information would be beneficial to the outcomes of this work in the case of SDM seems unlikely, as it has the ability to introduce significant errors into the prediction algorithm. I-Mutant2.0 output may be enhanced by the use of such input data, although further investigation is required.
All of the programs used within this study require different inputs and use algorithms of differing sensitivity. However, the need for more publicly available data relating to the tertiary structure appears to limit the utility of our methodology in identifying candidate nsSNPs of interest within a pathway setting.
Transgenic models
Although a robust genetic association in a clinical study provides some evidence of functionality of a variant in that gene or surrounding loci, it is also important that this is shown in functional studies, particularly given the limitations of bioinformatic approaches outlined above. A powerful tool for functional evaluation is the use of transgenic animal models, which can provide important information on genotype-phenotype relationships and help in evaluating the clinical implications of dysfunctional folate pathway genes. To date, however, only a limited number of folate pathway gene knockout mouse models have been developed and phenotypically characterized. Of these, both MTHFR and CBS display a hyperhomocysteinemia phenotype (Table 7) . A MAT1A-null mouse model has also been characterized. 89 This knockout has impaired liver regeneration and spontaneous hepatocellular carcinoma. The localization of these events is likely to be due to the high expression levels of MAT1A in hepatic tissue. 89 Knockout mice null for the FOLR1 homolog, Folbp1, 90 led to embryonic lethality, which could be reversed in heterozygote dams with folinic acid supplementation.
Conclusions
It is clear that polymorphisms in genes in the one-carbon folate pathway are associated with a dynamic range of clinical conditions. What appears to not be so dynamic is the scope of genetic polymorphisms investigated in this large number of studies. A functional polymorphism, such Abbreviations: nsSNP, non-synonymous SNP; SNP, single nucleotide polymorphism.
In silico analysis of the deleterious effects of non-synonymous SNPs in genes of the one-carbon folate pathway (a). nsSNPs determined as deleterious by programs are marked as black; white squares indicate a non-deleterious effect and gray an intermediate effect according to the scoring parameters indicated in (b). SNPs are ranked according to the number of black scores followed by the number of gray scores. Cross-hatched squares indicate where in sufficient input data is available to produce an output.
One-carbon folate pathway genetics DF Carr et al as the MTHFR 677C4T, given its clear and well-characterized effect on the enzymatic function of the protein and associated elevated homocysteine levels, is a good candidate polymorphism in clinical studies where folate disruption is believed to have a key function. However, there are more than 25 genes in the one-carbon folate and methionine pathways. It is entirely feasible that, with greater investigation of some of the 'lesser lights' of the folate pathway genes, other functionally relevant variants could be identified in disease association studies. The use of in silico techniques represents a potentially useful tool in the prediction of the deleterious effects of nsSNPs. However, at present, with the limited availability of structural data, it is difficult to perform such analysis on a pathway-wide scale, as we have with the one-carbon folate metabolism pathway. In future, a greater deposition of protein structure data on public databases will allow more thorough examination of all nsSNPs. This may improve sensitivity for detecting nsSNPs, which not only have a functional effect on the protein but also are associated with a phenotype. 
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